Table 1.
Baseline patient characteristics
| Characteristics | PA-TACE | NonPA-TACE | P-value |
|---|---|---|---|
| Sex, M/F | 94/8 | 67/11 | 0.176 |
| Age, years, median (range) | 55 (32–82) | 56 (24–78) | 0.6 |
| Child-Pugh status A/B/C | 62/5/1 | 57/4/0 | 0.233 |
| MELD score | 7 (6–10) | 7 (6–9) | 0.813 |
| Laboratory values, median (range) | |||
| WBC count, 109/L | 5.2 (2.0–9.6) | 5.5 (2.3–13.4) | 0.215 |
| Platelet count, 109/L | 154 (54–319) | 154 (34–367) | 0.561 |
| Hemoglobin, g/dL | 135 (84–169) | 142 (103–169) | 0.089 |
| Serum total bilirubin, mg/dL | 11.5 (6.9–135) | 13.5 (4.7–47.2) | 0.784 |
| Serum albumin, g/dL | 39.6 (30.8-59.3) | 40.9 (31.8-89.3) | 0.074 |
| INR | 1.10 (0–3.48) | 1.08 (0–1.33) | 0.003* |
| Serum creatinine, mg/dL | 67.7 (35.6–123.2) | 70.4 (47.3–97.4) | 0.516 |
| Serum alpha-fetoprotein, ng/mL | |||
| <20/≥20 | 30/42 | 40/27 | 0.034* |
| Tumor burden and distribution | |||
| Unifocal/multifocal | 78/24 | 62/16 | 0.63 |
| Maximal lesion diameter (cm) | 5.94±2.95 | 6.23±4.34 | 0.595 |
Note: *Significant difference (P<0.05).
Abbreviations: INR, international normalized ratio; PA-TACE, postoperative adjuvant TACE; MELD, Model of End-stage Liver Disease; WBC, white blood cell.